359 related articles for article (PubMed ID: 1532054)
21. [Effect of ondansetron hydrochloride injection and tablet against nausea and vomiting in lung cancer patients receiving carboplatin].
Miyamoto Y; Yagi K; Teramachi M; Oomasa M; Tomiyama K
Gan To Kagaku Ryoho; 1999 Jan; 26(1):125-30. PubMed ID: 9987508
[TBL] [Abstract][Full Text] [Related]
22. [Effects of intravenous and oral administration of ondansetron hydrochloride on chemotherapy-induced nausea and vomiting in patients with esophageal cancer].
Miyashita M; Onda M; Ikeda K; Bando K; Hagiwara N; Tsuchiya Y; Yoshiyuki T; Kiyama T; Saito T; Sasajima K; Yamashita K
Gan To Kagaku Ryoho; 1999 Oct; 26(11):1629-35. PubMed ID: 10553422
[TBL] [Abstract][Full Text] [Related]
23. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975
[TBL] [Abstract][Full Text] [Related]
24. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC
Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488
[TBL] [Abstract][Full Text] [Related]
25. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Carides G; Elmer M; Schmidt C; Evans JK; Horgan KJ
J Clin Oncol; 2003 Nov; 21(22):4105-11. PubMed ID: 14559891
[TBL] [Abstract][Full Text] [Related]
26. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
Van Belle S; Lichinitser MR; Navari RM; Garin AM; Decramer ML; Riviere A; Thant M; Brestan E; Bui B; Eldridge K; De Smet M; Michiels N; Reinhardt RR; Carides AD; Evans JK; Gertz BJ
Cancer; 2002 Jun; 94(11):3032-41. PubMed ID: 12115394
[TBL] [Abstract][Full Text] [Related]
27. Ondansetron--the first of a new class of antiemetic agents.
Chaffee BJ; Tankanow RM
Clin Pharm; 1991 Jun; 10(6):430-46. PubMed ID: 1829668
[TBL] [Abstract][Full Text] [Related]
28. The role of ondansetron in paediatric patients: a review of three studies.
Stevens RF
Eur J Cancer; 1991; 27 Suppl 1():S20-2. PubMed ID: 1831631
[TBL] [Abstract][Full Text] [Related]
29. Nurses' perceptions of antiemetic effectiveness.
Rhodes VA; McDaniel RW; Simms SG; Johnson M
Oncol Nurs Forum; 1995 Sep; 22(8):1243-52. PubMed ID: 8532549
[TBL] [Abstract][Full Text] [Related]
30. [Combined use of ondansetron and other anti-emetics to control cisplatin-induced nausea and vomiting].
Zeng WY
Zhonghua Zhong Liu Za Zhi; 1993 Mar; 15(2):118-21. PubMed ID: 8223120
[TBL] [Abstract][Full Text] [Related]
31. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials.
Gralla RJ; de Wit R; Herrstedt J; Carides AD; Ianus J; Guoguang-Ma J; Evans JK; Horgan KJ
Cancer; 2005 Aug; 104(4):864-8. PubMed ID: 15973669
[TBL] [Abstract][Full Text] [Related]
32. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community.
Hickok JT; Roscoe JA; Morrow GR; King DK; Atkins JN; Fitch TR
Cancer; 2003 Jun; 97(11):2880-6. PubMed ID: 12767103
[TBL] [Abstract][Full Text] [Related]
33. [Anti-emetic effect and safety of consecutive use of ondansetron injection in cisplatin-induced nausea and emesis].
Akasaka Y; Taguchi T; Ota K; Furue H; Niitani H; Tsukagoshi S; Ariyoshi Y; Ikeda M; Ohta J; Suminaga M
Gan To Kagaku Ryoho; 1992 Aug; 19(9):1359-74. PubMed ID: 1386977
[TBL] [Abstract][Full Text] [Related]
34. Comparative evaluation of the clinical efficacy and safety of ondansetron and metoclopramide in the prophylaxis of emesis induced by cancer chemotherapy regimens including cisplatin.
Advani SH; Gopal R; Dhar AK; Lal HM; Cooverji ND
J Assoc Physicians India; 1996 Feb; 44(2):127-30. PubMed ID: 10999066
[TBL] [Abstract][Full Text] [Related]
35. Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting.
Yeh YC; McDonnell A; Klinger E; Fowler B; Matta L; Voit D; Reddy P
J Oncol Pharm Pract; 2011 Sep; 17(3):179-85. PubMed ID: 20452991
[TBL] [Abstract][Full Text] [Related]
36. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
[TBL] [Abstract][Full Text] [Related]
37. [Examination on efficacy and safety of concurrent use of ondansetron hydrochloride and steroid in gynecological cancer patients on cisplatin].
Eguchi F; Taguchi T; Furue H; Ikeda M; Tsukakoshi S;
Gan To Kagaku Ryoho; 2001 Oct; 28(10):1423-9. PubMed ID: 11681251
[TBL] [Abstract][Full Text] [Related]
38. The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimes.
Schmoll HJ
Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S35-9. PubMed ID: 2533897
[TBL] [Abstract][Full Text] [Related]
39. [Examination of anti-emetic effect and safety of multiple intravenous doses of ondansetron in patients receiving nonplatinum anti-cancer drugs].
Nukariya N; Niitani H; Taguchi T; Furue H; Ota K; Tsukagoshi S; Ariyoshi Y; Ikeda M; Akasaka Y; Ohta J
Gan To Kagaku Ryoho; 1992 Aug; 19(9):1375-85. PubMed ID: 1386978
[TBL] [Abstract][Full Text] [Related]
40. [Investigation of anti-emetic effect of ondansetron tablet in multiple doses on nausea and emesis associated with cisplatin].
Suminaga M; Furue H; Taguchi T; Niitani H; Ota K; Tsukagoshi S; Ariyoshi Y; Ikeda M; Akasaka Y; Ohta J
Gan To Kagaku Ryoho; 1992 Sep; 19(11):1879-90. PubMed ID: 1387774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]